Literature DB >> 32204368

Liver Transplantation for Pediatric Liver Cancer.

Rakesh Sindhi1, Vinayak Rohan2, Andrew Bukowinski1, Sameh Tadros1, Jean de Ville de Goyet3, Louis Rapkin4, Sarangarajan Ranganathan5.   

Abstract

Unresectable hepatocellular carcinoma (HCC) was first removed successfully with total hepatectomy and liver transplantation (LT) in a child over five decades ago. Since then, children with unresectable liver cancer have benefitted greatly from LT and a confluence of several equally important endeavors. Regional and trans-continental collaborations have accelerated the development and standardization of chemotherapy regimens, which provide disease control to enable LT, and also serve as a test of unresectability. In the process, tumor histology, imaging protocols, and tumor staging have also matured to better assess response and LT candidacy. Significant trends include a steady increase in the incidence of and use of LT for hepatoblastoma, and a significant improvement in survival after LT for HCC with each decade. Although LT is curative for most unresectable primary liver sarcomas, such as embryonal sarcoma, the malignant rhabdoid tumor appears relapse-prone despite chemotherapy and LT. Pediatric liver tumors remain rare, and diagnostic uncertainty in some settings can potentially delay treatment or lead to the selection of less effective chemotherapy. We review the current knowledge relevant to diagnosis, LT candidacy, and post-transplant outcomes for these tumors, emphasizing recent observations made from large registries or larger series.

Entities:  

Keywords:  PRE-TEXT; chemotherapy; hepatoblastoma; hepatocellular carcinoma; histopathology; liver cancer; liver sarcoma; liver transplantation; neuroendocrine tumor; pediatric

Year:  2020        PMID: 32204368     DOI: 10.3390/cancers12030720

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  6 in total

1.  Living donor liver transplantation in an infant patient with progressive familial intrahepatic cholestasis along with hepatocellular carcinoma: a case report.

Authors:  Jung-Man Namgoong; Shin Hwang; Dae-Yeon Kim; Chul-Soo Ahn; Hyunhee Kwon; Suhyeon Ha; Kyung Mo Kim; Seak Hee Oh
Journal:  Korean J Transplant       Date:  2022-03-31

2.  Liver transplantation in pediatric patients with progressive familial intrahepatic cholestasis: Single center experience of seven cases.

Authors:  Jung-Man Namgoong; Shin Hwang; Hyunhee Kwon; Suhyeon Ha; Kyung Mo Kim; Seak Hee Oh; Seung-Mo Hong
Journal:  Ann Hepatobiliary Pancreat Surg       Date:  2022-02-28

Review 3.  Not only a small liver - The pathologist's perspective in the pediatric liver transplant setting.

Authors:  Alessandro Gambella; Luca Mastracci; Chiara Caporalini; Paola Francalanci; Claudia Mescoli; Jacopo Ferro; Rita Alaggio; Federica Grillo
Journal:  Pathologica       Date:  2022-02

4.  Competitive risk analysis of the therapeutic value of liver transplantation for liver cancer in children: A population-based study.

Authors:  Huiwu Xing; Chenyu Yang; Bingqian Tan; Mingman Zhang
Journal:  Front Surg       Date:  2022-08-31

5.  Outcomes following liver transplantation in young infants: Data from the SPLIT registry.

Authors:  Ajay K Jain; Ravinder Anand; Stacee Lerret; George Yanni; Jia-Yuh Chen; Saeed Mohammad; Majella Doyle; Greg Telega; Simon Horslen
Journal:  Am J Transplant       Date:  2020-09-05       Impact factor: 8.086

6.  Development of a Predictive Immune-Related Gene Signature Associated With Hepatocellular Carcinoma Patient Prognosis.

Authors:  Jiasheng Lei; Dengyong Zhang; Chao Yao; Sheng Ding; Zheng Lu
Journal:  Cancer Control       Date:  2020 Jan-Dec       Impact factor: 3.302

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.